Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Prilocaine" patented technology

Prilocaine (/ˈpraɪləˌkeɪn/) is a local anesthetic of the amino amide type first prepared by Claes Tegner and Nils Löfgren. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a topical preparation for dermal anesthesia (lidocaine/prilocaine or EMLA), for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA).

Method for simultaneously determining ritocaine and prilocaine in plasma based on liquid chromatography-tandem mass spectrometry (LC-MS / MS) technology

The invention provides a method for simultaneously determining ritocaine and prilocaine in blood plasma based on a liquid chromatography-tandem mass spectrometry (LC-MSMS) technology. The specific operation of the method comprises the following steps: adding an internal standard solution and an organic solvent into a plasma sample, and ensuring full extraction of lidocaine and prilocaine through vortex mixing. And separating by using a centrifugal technology, and collecting supernate as a pretreated sample to be detected. An Eclipse Plus C18 chromatographic column is adopted for isocratic elution, effective separation of lidocaine and prilocaine is achieved, and then a sample is subjected to mass spectrometric detection. A standard curve is drawn based on the mass spectrum peak area ratio, a regression equation is obtained, and the concentration of lidocaine and prilocaine in the sample to be detected is obtained through calculation. The method has the characteristics of simplicity and convenience in pretreatment operation, low plasma consumption, short analysis time and high sensitivity, and is suitable for detection of lidocaine and prilocaine in plasma and clinical pharmacokinetic research of the lidocaine cream.
Owner:SUZHOU HAIKE MEDICAL TECH CO LTD

Compound lidocaine cream as well as preparation method and application thereof

The invention relates to the technical field of medicines, and particularly discloses compound lidocaine cream as well as a preparation method and application thereof. The invention provides compound lidocaine emulsifiable paste. The compound lidocaine emulsifiable paste is specifically prepared from the following components in parts by weight: 22 to 26 parts of lidocaine, 22 to 26 parts of prilocaine, 13 to 17 parts of solubilizer, 9 to 11 parts of carbomer, 3 to 5 parts of sodium hydroxide and 0.02 to 0.06 part of penetration enhancer, the total amount is 1000 parts. The solubilizer is formed by mixing polyoxyethylene hydrogenated castor oil and poloxamer 188 in a weight ratio of (10-15): (1-4); the penetration enhancer is prepared by mixing L-ethyl lactate and oleic acid in a weight ratio of (1-4): (0.2-1). The compound lidocaine emulsifiable paste prepared by the invention has good safety, and the compound lidocaine emulsifiable paste has the effects of quicker effect taking, deeper anesthetic effect and longer duration time.
Owner:BEIJING UNIS PHARMA

Levadicaine pre-packaging application and preparation method thereof

The invention relates to the field of medical application, in particular to a riptacaine pre-packaged application and a preparation method thereof. The lidocaine pre-packaged application is formed by packaging an application base material and anesthetic liquid together, and the anesthetic liquid is prepared from the following raw materials in parts by mass: 0.1 to 0.3 part of sodium hyaluronate, 0.1 to 0.3 part of a thickening agent, 7 to 13 parts of an alcohol penetration enhancer, 3 to 6 parts of a nonionic surfactant, 0.3 to 0.8 part of poloxamer and 1 to 3 parts of lidocaine, the anesthetic comprises the following components in parts by mass: 1-3 parts of prilocaine, 0.1-0.2 part of epsilon-polylysine, a pH regulator for regulating the pH value of the anesthetic liquid to 7.0-8.0, and the balance of water, totaling 100 parts by mass. According to the invention, by adding a small amount of epsilon-polylysine, the epsilon-polylysine not only has an antibacterial effect, but also can obviously improve the stability of the riptacaine liquid medicine, and through long-term storage and high-temperature acceleration experiments, the increase speed of related impurities is obviously slowed down, so that the reliability and safety of the pre-sealed riptacaine skin surface anesthesia application can be improved.
Owner:BEIJING JINGYU YIMEI BIOTECHNOLOGY CO LTD

A method of preparing prilocaine

The application discloses a preparation method of pramoxine, which comprises the following steps: taking 1,4-p-dibromobenzene and n-butanol as raw materials, and adopting cheap and easily obtained nickel salt as a catalyst, and under the action of catalytic amount of silane reagent, a ligand and an organic base, 1-bromo-4-butoxybenzene is synthesized through C-O coupling reaction; then, 1-bromo-4-butoxybenzene and 3-(4-morpholinyl)-1-propanol are subjected to C-O coupling reaction through the same method to obtain pramoxine. The preparation method has the characteristics of mild conditions, all the raw materials are commercially available and low in price, simple synthesis steps, high yield, high atom economy and the like, and is expected to realize industrialized production of pramoxine.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Method for detecting nitrosamine impurity in bulk drug prilocaine

The invention relates to the technical field of drug detection, in particular to an exclusive, high-sensitivity, anti-interference and simple-operation quantitative detection method capable of simultaneously aiming at three isomeride nitrosamine impurities in a raw material drug prilocaine. According to the method disclosed by the invention, detection analysis is carried out by virtue of a liquid chromatograph-mass spectrometer, and quantitative detection of three nitrosamine impurities which are very close in structure and large in impurity limit requirement difference in the raw material medicine prilocaine is realized by screening liquid chromatography conditions, so that the quality controllability of the raw material medicine is improved, the carcinogenic risk can be reduced from the source, and the method is suitable for industrial production. The medication safety of a patient is ensured.
Owner:FRONT PHARM PLC